Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients.

Wägner, Ana M.; Pérez, Antonio; Calvo, F. L.; Bonet, Rosa; Castellví, A; Ordóñez, J.

doi:10.2337/diacare.22.5.812

Cited by 61 publications

(19 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such changes in lipid levels have been shown to be associated with less CAD (24)(25)(26). Because apo B is independently associated with cardiovascular disease and identifies high-risk phenotypes in normocholesterolemic type 2 diabetic patients (27), the 30% reduction induced by Abalon is noteworthy. It could be argued that the apparent difference in change in apo B100 versus the change in LDL cholesterol is enigmatic because there is one apo B molecule in the LDL particle.…”

Section: Glucose and Insulin Responsesmentioning

confidence: 98%

Beneficial Effects of a Soy-Based Dietary Supplement on Lipid Levels and Cardiovascular Risk Markers in Type 2 Diabetic Subjects

et al. 2001

View full text Add to dashboard Cite

OBJECTIVE -Consumption of soy protein has recently been shown to improve the blood lipid levels in nondiabetic subjects. The purpose of this study was to evaluate if a dietary supplement of soy protein, isoflavones, and cotyledon fiber (Abalon) affects cardiovascular risk markers, blood glucose, and insulin levels in type 2 diabetic subjects. RESEARCH DESIGN AND METHODS RESULTS -The results are expressed as means ± SD. The percentage mean treatment difference between Abalon and placebo demonstrated significantly lower mean values afterAbalon for LDL cholesterol (10 ± 15%, P Ͻ 0.05), LDL/HDL ratio (12 ± 18%, P Ͻ 0.05), apolipoprotein (apo) B100 (30 ± 38%, P Ͻ 0.01), triglycerides (22 ± 10%, P Ͻ 0.05), and homocysteine (14 ± 21%, P Ͻ 0.01), whereas the total cholesterol value tended to be less significant but still lower (8 ± 15%, P Ͻ 0.08). No change occurred in HDL cholesterol, apo B100/apo A1 ratio, plasminogen activator inhibitor 1, factor VIIc, von Willebrand factor, fibrinogen, lipoprotein(a), glucose, HbA 1c , or 24-h blood pressure. CONCLUSIONS -These results indicate beneficial effects of dietary supplementation withAbalon on cardiovascular risk markers in type 2 diabetic subjects. This improvement is seen even in individuals with near-normal lipid values.

show abstract

Section: Glucose and Insulin Responsesmentioning

confidence: 98%

Beneficial Effects of a Soy-Based Dietary Supplement on Lipid Levels and Cardiovascular Risk Markers in Type 2 Diabetic Subjects

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Mean apolipoprotein B concentrations were greater than 120 mg/dL in both subgroups, a threshold predictive of ischemic heart disease even in the face of normal cholesterol concentrations. 19,28 Further work is needed to determine the relative risk conferred by elevated apolipoprotein B in women with a history of eclampsia.…”

Section: Discussionmentioning

confidence: 99%

C-Reactive Protein Is Elevated 30 Years After Eclamptic Pregnancy

et al. 2008

View full text Add to dashboard Cite

Abstract-Women with a history of preeclampsia or eclampsia (seizure during preeclamptic pregnancy) are at increased risk for cardiovascular disease after pregnancy for reasons that remain unclear. Prospective studies during pregnancy suggest that inflammation, dyslipidemia, and insulin resistance are associated with increased risk of preeclampsia. Elevated serum C-reactive protein (CRP Ͼ3 mg/L) is an indicator of inflammation and cardiovascular risk. We hypothesized that Icelandic postmenopausal women with a history of eclampsia would manifest higher concentrations of serum CRP than Icelandic postmenopausal controls with a history of uncomplicated pregnancies. We also asked whether elevated CRP is associated with the dyslipidemia and insulin resistance previously identified in this cohort. CRP, measured by high-sensitivity enzyme-linked immunoassay, was higher in women with prior eclampsia (nϭ25) than controls (nϭ28)

show abstract

“…Individuals with type 2 diabetes have an increased risk of cardiovascular disease, which is closely associated with elevation of the plasma levels of apolipoprotein B (apoB)-containing VLDL and LDL (2,3). Metabolic labeling studies have indicated that the increased plasma levels of VLDL and LDL in individuals with diabetes are caused, at least in part, by increased hepatic secretion of apoB-containing lipoproteins (4,5).…”

mentioning

confidence: 99%

Hepatic Expression of Microsomal Triglyceride Transfer Protein and In Vivo Secretion of Triglyceride-Rich Lipoproteins Are Increased in Obese Diabetic Mice

2002

View full text Add to dashboard Cite

Secondary hyperlipidemia is a major cardiovascular risk factor in individuals with type 2 diabetes. Increased hepatic production of apolipoprotein B (apoB)-containing lipoproteins contributes to the elevated plasma levels, but the mechanism is poorly understood. Recent results have established that microsomal triglyceride transfer protein (MTP) is rate limiting for the assembly and secretion of apoB-containing lipoproteins. To better understand the mechanism of type 2 diabetes-associated hyperlipidemia, we quantified hepatic MTP mRNA levels, hepatic microsomal triglyceride transfer activity, and in vivo triglyceride secretion from the liver in two diabetic mouse models. Obese diabetic (ob/ob) mice had 45% higher (P ‫؍‬ 0.006) hepatic MTP mRNA levels, 54% higher (P < 0.0001) microsomal triglyceride transfer activity, and 70% higher (P < 0.0001) in vivo triglyceride secretion rates compared with ob/؉ control mice. In contrast, in lean streptozotocin-treated diabetic mice, hepatic MTP mRNA levels were unchanged, whereas microsomal triglyceride transfer activity and in vivo triglyceride secretion rates were marginally decreased. These studies suggest that obesity-induced type 2 diabetes in mice confers increases in hepatic MTP expression and secretion of triglyceride-rich lipoproteins. High blood glucose and altered hepatic expression of sterol regulatory element binding protein genes play a minor role in this diabetic response. Diabetes 51: 1233-1239, 2002 T he incidence and prevalence of type 2 diabetes are rapidly rising (1). Individuals with type 2 diabetes have an increased risk of cardiovascular disease, which is closely associated with elevation of the plasma levels of apolipoprotein B (apoB)-containing VLDL and LDL (2,3). Metabolic labeling studies have indicated that the increased plasma levels of VLDL and LDL in individuals with diabetes are caused, at least in part, by increased hepatic secretion of apoB-containing lipoproteins (4,5). Hence, a better understanding of the factors in patients with type 2 diabetes that mediate increased lipoprotein secretion from the liver could potentially lead to rational therapeutic strategies to prevent cardiovascular disease in this patient group.During the past 5 years, it has become evident that microsomal triglyceride transfer protein (MTP) is rate limiting for the production of apoB-containing VLDL (6 -10). MTP is an exclusively intracellular protein (6). Its principal role is to transfer lipids onto the apoB polypeptide in the endoplasmic reticulum of lipoprotein-secreting cells (6). Reduction of the MTP activity in animals by MTP inhibitor drugs (7) or genetic manipulations (11,12) lowers plasma lipoprotein levels, whereas adenoviral overexpression of an MTP cDNA in mouse liver in vivo increases hepatic secretion of triglyceride-rich apoB-containing lipoproteins (13,14).Studies of cultured liver cells suggest that insulin and glucose reduce the expression of the MTP gene (15); the MTP gene promoter region contains a putative insulinresponsive element (16). Also, r...

show abstract

Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients.

Cited by 61 publications

References 1 publication

Beneficial Effects of a Soy-Based Dietary Supplement on Lipid Levels and Cardiovascular Risk Markers in Type 2 Diabetic Subjects

Beneficial Effects of a Soy-Based Dietary Supplement on Lipid Levels and Cardiovascular Risk Markers in Type 2 Diabetic Subjects

C-Reactive Protein Is Elevated 30 Years After Eclamptic Pregnancy

Hepatic Expression of Microsomal Triglyceride Transfer Protein and In Vivo Secretion of Triglyceride-Rich Lipoproteins Are Increased in Obese Diabetic Mice

Contact Info

Product

Resources

About